Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

Epigenetic modifications, therefore, provide exciting new avenues for prostate cancer research ... provide attractive therapeutic opportunities. Many promising agents have been identified that ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Although carbon ion radiation led to a decline in urinary function among patients with prostate cancer, function returned to ...

About half of men with medium-risk prostate cancer have just one tumour, occupying only 5 to 10 per cent of the prostate, yet ...

Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...

The oncology sector is experiencing an unprecedented wave of innovation in 2025, with rising cancer rates fueling the demand for better detection, treatment, and investment in life-saving technologies ...